• High serum iron was associated with elevated levels of Th 2 category of cytokines, heightened immune activation, faster decline in CD4 + T lymphocyte count and higher viral set point. (scirp.org)
  • The present prospective study, carried out over fifteen years, describes the pattern of natural course of disease progression in a group of ART naive male professional blood donors with asymptomatic HIV-1 infection in relation to serum iron status, viral load, peripheral CD4 + T lymphocyte count, serum levels of cytokines and immune activation markers viz. (scirp.org)
  • IRIS was independently associated with CD4 cell count less than 50 cells/μl vs. at least 200 cells/μl [odds ratio (OR) 5.0] and a viral load of at least 5.0 log(10) copies vs. less than 4.0 log(10) copies (OR 2.3). (nih.gov)
  • A simplified system to describe four clinical stages of HIV-related disease, based on clinical parameters (symptoms, weight loss and different opportunistic infections) rather than decreasing CD4 cell count. (aidsmap.com)
  • By contrast, any degree of HIV-RNA replication both at M6 and M12 was associated with a flat or a decreasing CD4 cell count slope. (ufrgs.br)
  • Median baseline CD4 count stood at 524. (natap.org)
  • The training was formal education, low baseline CD4, and un- given by the primary investigator on how to employment were found to be significantly associated administer the cognitive assessment tool. (who.int)
  • An objective response was found in 25% (95% CI, 12.1%-42.2%) of patients, all of whom had baseline CD4 count of 200 or more. (eatg.org)
  • There were also no statistically significant changes in CD4 count from baseline to the fourth treatment cycle. (eatg.org)
  • Although CD4-cell rebounds slowed in later years of treatment, they did continue to improve, particularly among HIVers who began treatment with lower baseline counts, according to the study of 505 Dutch HIV-positive adults. (hivplusmag.com)
  • Baseline absolute CD4 counts and viral loads in HIV positive individuals with lymphogranuloma venereum: the results of a multi-centre case control study in the UK, LGV-net. (natap.org)
  • However, CD8 and CD4 counts recovered to baseline levels in only 30% and 21% of patients, respectively. (bmj.com)
  • Conclusions Lymphocyte counts recovered to LLN after a single course of alemtuzumab in approximately 8 months (B cells) and 3 years (T cell subsets), but usually did not recover to baseline values. (bmj.com)
  • Summary of results: 70 patients (15 female) with a median CD4 cell count of 210/μl (47-949) and HIV-RNA PCR of 140,000 copies/ml (2,500-2,000,000) at baseline received TDF, NVP and 3TC/FTC, and were treated for a median of 68 weeks (16-278). (uni-frankfurt.de)
  • The CD4 cell count among persons with newly diagnosed HIV infection is a measure of immune deficiency and the median CD4 count among newly diagnosed persons is an important population-level indicator of the timeliness of HIV diagnosis following infection. (etedashboardny.org)
  • The graph below shows a steady increase in the median CD4 count among persons with newly diagnosed HIV in New York who had a CD4 count within 3 months of their diagnosis, from 315 cells/mm 3 in 2006 to 378 cells/mm 3 in 2013. (etedashboardny.org)
  • 1 Even if the rate of increase in the median CD4 count at diagnosis of 9 cells/mm 3 each year continued in New York, it would be about 13 years (2028) before it reaches 500 cells/ mm 3 , when only half of newly diagnosed persons would be in a position to initiate ART at the threshold of that was shown to be more protective in the START trial. (etedashboardny.org)
  • The increase in the median CD4 count at diagnosis in New York since 2006 is likely due (at least in part) to the impact of expanded testing and linkage efforts on earlier diagnosis. (etedashboardny.org)
  • Mean CD4+ count at time of diagnosis is ~50/µL. (wikipedia.org)
  • The investigators interviewed the men about their sexual history and requested CD4 counts and viral loads recorded in the men in the months before their LGV diagnosis or inclusion in this study. (natap.org)
  • At the time of first HZ diagnosis, the median age was 39 years, CD4 count was 459 and VL was 1950 copies. (aahivm.org)
  • The study was limited by a small number of observations on CD4 count at diagnosis and by including transmission only to first generation partners of the index patients. (cdc.gov)
  • After a median of 4 years follow-up (3,632 child-years), 69 children had an ERC-confirmed TB diagnosis. (biomedcentral.com)
  • PGT121 reduced plasma HIV RNA levels by a median of 1.77 log in viremic participants, with a viral load nadir at a median of 8.5 days. (nature.com)
  • A high viral load was strongly associated to the oral lesions occurrence independently of CD4 + cell count. (medscape.com)
  • In 1989, using a method based on rates of CD4 cell count decline, we estimated that 60 men would have AIDS by 2000 ( table ). (bmj.com)
  • 50 copies/ml and their median CD4 cell count is 326 (139-593) 10 6 cells/l. (bmj.com)
  • Before entering (infecting) a CD4 T cell (that will become a "host" cell), HIV binds to the CD4 receptor and its coreceptor. (aidsmap.com)
  • We studied 2,610 patients seen during 1996-2007 who initiated or resumed highly active combination antiretroviral therapy (cART) and, during the next 6 months, demonstrated a decline in plasma HIV-RNA viral load of at least 0.5 log(10) copies/ml or an increase of at least 50% in CD4 cell count per microliter. (nih.gov)
  • Severe immunosuppression was prevalent (median CD4 count = 42 cell/µL). (who.int)
  • The secondary endpoints were changes in anti-PGT121 antibody titers and CD4 + T-cell count, and development of HIV-1 sequence variations associated with PGT121 resistance. (nature.com)
  • Absolute and relative CD4 + T-cell counts did not change following PGT121 infusion in HIV-infected participants. (nature.com)
  • Everyone knows that antiretroviral drugs can produce increases in CD4-cell counts and drops in viral levels, but just how long do those improvements continue? (hivplusmag.com)
  • We compared clinical outcomes among HIV-infected participants receiving ART who were randomized to viral load (VL) and CD4 cell count monitoring in comparison to CD4 cell count monitoring alone in Tororo, Uganda. (biomedcentral.com)
  • or clinical monitoring, quarterly CD4 cell counts and quarterly VL testing (CD4-VL). (biomedcentral.com)
  • At enrolment the median age was 38 years and the median CD4 cell count was 134 cells/μL. (biomedcentral.com)
  • We found no differences in clinical outcomes associated with the addition of quarterly VL monitoring to quarterly CD4 cell count monitoring. (biomedcentral.com)
  • However, VL testing remains relatively costly and more technologically challenging in comparison to clinical or CD4 cell count monitoring in resource limited settings. (biomedcentral.com)
  • However, the study found no difference in clinical outcomes between participants who were randomized to VL and CD4 cell count monitoring in comparison to CD4 cell count monitoring, alone after 3 years of follow-up. (biomedcentral.com)
  • The only other randomized trial which has directly compared clinical outcomes between patients monitored with VL and CD4 cell counts with those monitored with CD4 cell counts alone, conducted in Thailand found similar results. (biomedcentral.com)
  • The median CD4 lymphocyte cell count was 70 (27-160) cells/mm3, and 90% of patients were experienced in combined antiretroviral therapy. (usp.br)
  • The CD4 cell percentage measures the proportion of all white blood cells that are CD4 cells. (aidsmap.com)
  • Women participants were about five years older than men, on average, and they had a lower median CD4 T-cell count. (realhealthmag.com)
  • TB-related IRIS is a frequent complication in people with HIV who start TB treatment with low CD4 cell counts. (hivandhepatitis.com)
  • 50 cells/mm 3 ), those with disseminated TB (symptoms in organs other than the lungs), and those who experience very large CD4 cell count increases after starting treatment are known to have a higher risk of developing TB-IRIS. (hivandhepatitis.com)
  • People were eligible to take part in the study if they had CD4 cell counts below 100 cells/mm 3 , had started TB treatment less than 30 days prior to joining the study, and were antiretroviral-naive. (hivandhepatitis.com)
  • the median CD4 cell count on study entry was 49 cells/mm 3 in the prednisone arm and 51 in the placebo arm and viral loads were high (5.5 log and 5.4 log, respectively). (hivandhepatitis.com)
  • CD4 cell counts increased by 150 cells/mm 3 in the placebo arm and 164 cells/mm 3 in the prednisone arm, showing that the corticosteroid did not impede immune reconstitution. (hivandhepatitis.com)
  • 12 TB infection can occur at any CD4 T lymphocyte (CD4) cell count, although the risk increases with progressive immunodeficiency. (hiv.gov)
  • Description: The RPA-T4 monoclonal antibody reacts with human CD4, a 59 kDa cell surface receptor expressed by a majority of thymocytes, subpopulation of mature T cells (T-helper cells) and in low levels on monocytes. (thermofisher.com)
  • CD4 functions to initiate or augment the early phase of T-cell activation through its association with the T-cell receptor complex and protein tyrosine kinase, Lck. (thermofisher.com)
  • Background: Changes in CD4 cell counts are poorly documented in individuals with low or moderate-level viremia while on antiretroviral treatment (ART) in resource-limited settings. (ufrgs.br)
  • We assessed the impact of on-going HIV-RNA replication on CD4 cell count slopes in patients treated with a first-line combination ART. (ufrgs.br)
  • The relationships between mean CD4 cell count change and HIV-RNA at 6 and 12 months after ART initiation (M6 and M12) were assessed by linear mixed models adjusted for gender, age, clinical stage and year of starting ART. (ufrgs.br)
  • Results: 3,338 patients were included (14 cohorts, 64% female) and the group had the following characteristics: a median follow-up time of 1.6 years, a median age of 34 years, and a median CD4 cell count at ART initiation of 107 cells/μL. (ufrgs.br)
  • All patients with suppressed HIV-RNA at M12 had a continuous increase in CD4 cell count up to 18 months after treatment initiation. (ufrgs.br)
  • Multivariable analysis using HIV-RNA thresholds of 10,000 and 5,000 copies confirmed the significant effect of HIV-RNA on CD4 cell counts both at M6 and M12. (ufrgs.br)
  • Nevertheless, he added, such patients deserve "a comprehensive workup including skin biopsy with T-cell receptor clonality assay, blood cell counts with flow cytometry analysis, serum lactate dehydrogenase, and documentation of possible adenopathy, followed with imaging studies and/or local biopsies in cases with abnormal results. (medscape.com)
  • Median peak ALT level was 665 U/L (range: 72--5,291 U/L). No other cause for the patients' elevated ALT levels was found (e.g., no new infection with hepatitis A or B virus and no new drug therapy). (cdc.gov)
  • The Royal Free Hospital haemophilia cohort, consisting of 111 men with haemophilia infected with HIV after treatment with contaminated clotting factor concentrates (median age 22 (range 2-77) years at infection), has been described previously. (bmj.com)
  • TROGARZO, a CD4-directed post-attachment HIV-1 inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. (nih.gov)
  • Challenging a hypothesis about development of lymphogranuloma venereum (LGV) in HIV-infected gay men, researchers in Great Britain found that a lower CD4 count and a higher viral load do not predispose men to this often painful sexually transmitted infection [1]. (natap.org)
  • The cases and two control groups all had a median age around 40 and a statistically equivalent median duration of HIV infection: 4.7 years in cases, 5.5 years in symptomatic controls, and 7.1 years in asymptomatic controls (P = 0.137 versus cases). (natap.org)
  • The researchers also found that the slower rate of disease progression in those with a dual infection was reflected in higher numbers of CD4-positive T cells and lower levels of viral diversity at similar time points after infection. (health.am)
  • The researchers found that the median time to AIDS - defined by CD4 count, clinical signs, or death with AIDS symptoms - was 104 months, or 8.7 years, in participants with dual infection compared with 68 months, or 5.7 years in those with HIV-1 only. (health.am)
  • They also found that the 20 who got HIV-2 first had an even longer median time to AIDS - 129 months, or 10.75 years, which was also significantly greater, at P=0.007, than the time for those with HIV-1 infection only. (health.am)
  • Investigators have evaluated groups of persons with HIV infection for their ability to mount a DTH response and have related the results to other measures of HIV infection -- most commonly, CD4 T-lymphocyte counts. (cdc.gov)
  • Current HAART use was independently associated with low risk of in-hospital mortality (OR 0.33), while central nervous system symptoms (OR 4.12), sepsis (OR 6.98) and low total lymphocyte counts (OR 3.60) were associated with increased risk. (who.int)
  • Approximately one half of deaths (45.5%) were from AIDS-related causes and 74 deaths (61.2%) occurred in individuals who had received HAART: patients had been exposed to a median of seven (range 2-14) antiretroviral drugs and two-fifths had started treatment in the pre-HAART era. (nih.gov)
  • Of the patients exposed to HAART for at least 6 months and who experienced viral rebound, information was available on resistance for 26 (21.5% of the total deaths) and 19 of those tested had at least one resistance mutation (median 5, range, 1-16). (nih.gov)
  • We ran the model for 10,000 index patients for each setting, examining alternative scenarios, excluding and including transmission to partners, and assuming HAART was initiated at a CD4 count of either 350 or 500 cells/µL. (cdc.gov)
  • Screening patients in STD clinics, who have less-advanced disease, was cost-effective compared with ED screening when treatment with HAART was initiated at a CD4 count of 500 cells/µL. (cdc.gov)
  • The median CD4 count among these newly diagnosed persons increased at an average rate of about 9 cells/mm 3 per year during 2006-2013. (etedashboardny.org)
  • However, it is concerning that the trend appears to have plateaued in recent years and that in 2013 the median CD4 count was only 378 cells per mm 3 . (etedashboardny.org)
  • Importantly, the recent START trial showed that initiating ART before the CD4 count drops below 500 cells/mm 3 (versus waiting until the CD4 count dropped below 350 cells/mm 3 ) resulted in major reductions in the risk of serious AIDS events, serious non-AIDS events, and death. (etedashboardny.org)
  • CD4 T cells are called that way because they have a protein called CD4 on their surface. (aidsmap.com)
  • The median CD4 count in patients infected with HIV who develop nocardiosis is approximately 35 cells/µL. (medscape.com)
  • Participants were able to participate if they had a CD4 count of 100 cells/mL and had effective ART for 4 weeks. (eatg.org)
  • The median CD4 count was 315 (228-441) cells/mL. (eatg.org)
  • median recovery times for CD8 (LLN ≥0.2×10 9 cells/l) and CD4 lymphocytes (LLN ≥0.4×10 9 cells/l) were 20 months and 35 months, respectively. (bmj.com)
  • CD4-cells, HIV-RNA-PCR, SAQ and RTV drug-levels and metabolic parameters were compared. (uni-frankfurt.de)
  • CD4 cells rose up to cells/μl 322 (119-1075) and 75% of the patients remained on treatment. (uni-frankfurt.de)
  • The median CD4 count was 203 cells/µl (range 24 - 540) for HIV-infected patients on ART and 74 cells/µl (range 2 - 276) for those not on ART ( p =0.012). (scielo.org.za)
  • CD4 is primarily expressed in a subset of T-lymphocytes, also referred to as T helper cells, but may also be expressed by other cells in the immune system, such as monocytes, macrophages, and dendritic cells. (thermofisher.com)
  • A randomized, open-label strategy trial was conducted in HIV-1-infected women with CD4 counts ≥350 cells/mm 3 (or ≥country-specific ART threshold if higher) and their breastfeeding HIV-1-uninfected newborns. (medscape.com)
  • 97% of women were World Health Organization Clinical Stage I, median screening CD4 count 686 cells/mm 3 . (medscape.com)
  • The 20 patients have received a median of seven (3-11) antiretroviral drugs and have been exposed to antiretroviral therapy for a median of 9.9 (1.0-16.8) years. (bmj.com)
  • median viral load was 2.7 log(10) copies/ml. (nih.gov)
  • Overall median viral load for all three groups lay below 40 copies. (natap.org)
  • Median viral loads of men not taking antiretrovirals also proved statistically equivalent in 19 cases (23,374.5 copies), 14 symptomatic controls (13,000 copies), and 11 asymptomatic controls (15,676 copies) (P = 0.548). (natap.org)
  • Almost all participants, 96%, took antiretroviral therapy, 82% had a viral load below 40 copies, and median CD4 count stood at 620. (natap.org)
  • According to a Dutch study presented at the 13th Conference on Retroviruses and Opportunistic Infections, improvements in CD4 levels continue even after seven years of treatment. (hivplusmag.com)
  • Median survival is 10 to 18 months in immunocompetent patients, and less in those with AIDS. (wikipedia.org)
  • The addition of IV methotrexate and folinic acid (leucovorin) may extend survival to a median of 3.5 years. (wikipedia.org)
  • If radiation is added to methotrexate, median survival time may increase beyond 4 years. (wikipedia.org)
  • However, the duration of response with radiotherapy alone remains short, with median survival after treatment with radiotherapy just 18 months. (wikipedia.org)
  • Three-year survival rates, as well as changes in CD4 counts and viral load, were evaluated to determine the risk factors for treatment failure. (aidsmap.com)
  • Reconstitution time was expressed as a geometric mean or, when a non-negligible number of individuals failed to recover, as a median using survival analysis. (bmj.com)
  • Overall, ARROW showed that CD4 monitoring, compared with clinical monitoring alone, provided some clinical benefit after the first year on ART, but 5-year survival was very high overall (96%), supporting prioritisation of ART rollout over access to laboratory monitoring. (prolekare.cz)
  • Median survival duration (months) in the PT versus non-PT categories of ARI was 47 (95% CI as 42,48) versus 95 (95% CI as 90,100) in subgroup I and 71 (95% CI as 65,76) versus 107 (95% CI as 102,112) in subgroup II ( P (scirp.org)
  • Kaplan Meier plots, median survival times, and Log-rank test were used to describe the data and compare survival distribution between groups. (bvsalud.org)
  • Association between time to viral clearance and determinants was assessed using the Cox proportional hazard survival model, where hazard ratio, P-value, and 95% CI for hazard ratio were used for testing significance Results: The Median time to viral clearance was 16 days. (bvsalud.org)
  • When follow-up ended, 13,950 participants (48%) had taken one or more INSTIs for a median of 32 months. (natap.org)
  • The median number of doses for the participants was 5.5 (4-13). (eatg.org)
  • We randomized 1211 participants to the three original study arms and 331 surviving participants in the clinical monitoring arm were re-randomized to the CD4-VL and CD4 only arms. (biomedcentral.com)
  • Median age of participants stood at 44 years, 57% were women, 52% had black or mixed skin color, and 42% were current or former smokers. (natap.org)
  • Participants could have any CD4 count but could not have hepatitis B virus (HBV) or viral mutations conferring resistance to non-nucleoside reverse transcriptase inhibitors, with the exception of a mutation known as K103N. (poz.com)
  • The median age of participants was 34 years old, and 11 percent were 50 years old or older. (poz.com)
  • The median initial CD4 count was 444 and the median CD4 count after the initial 20 weeks of oral therapy that all participants received was 625. (poz.com)
  • Participants began ART a median of 17 days after TB treatment. (hivandhepatitis.com)
  • We therefore investigated virological outcomes and resistance in the ARROW randomised trial (ISRCTN24791884), which compared first-line ART regimens and CD4 monitoring strategies in children and adolescents in Uganda and Zimbabwe [ 8 ]. (prolekare.cz)
  • There was no evidence of differences between 3NRTI and 2NRTI+NNRTI long-term maintenance regimens in terms of clinical outcomes or CD4, but medium-term virological suppression was poorer with 3NRTI, supporting 2NRTI+NNRTI becoming the WHO-recommended first-line regimen for children as of 2013. (prolekare.cz)
  • The analysis included 29,340 people with HIV and a median age of 44 years. (natap.org)
  • Through a median follow-up of 6.18 years, 1078 new cancers developed (243 AIDS cancers and 835 non-AIDS cancers) for an incidence of 6.7 cases per 1000 person-years. (natap.org)
  • Follow-up time-calculated from seroconversion date to the date of death, last clinic visit (for those lost to follow-up), or 31 December 2004-ranged from 0.8 to 25.1 years (median 14.3). (bmj.com)
  • The 23 patients remaining under care at the centre (14 patients have transferred elsewhere) have been followed for a median of 22.7 (19.7-25.1) years. (bmj.com)
  • The median (IQR) age of the cohort was 54.6 (47.5-59.3) years, 91.7% were male, and 58.3% were non-Hispanic White. (eatg.org)
  • Over a median of 5.2 years of follow-up, 37 deaths and 35 new OIs occurred in the VL-CD4 arm patients, 39 deaths and 42 new OIs occurred in CD4-only patients. (biomedcentral.com)
  • The median age was 42.8 [34-51] years, and 61% were men. (usp.br)
  • The median age was 9.6 years (Interquartile Range (IQR), 7.0 to 11.8 years), most of them (31/48, 64.6%) were boys and 27 (56.3%) were from CHBAH. (wits.ac.za)
  • Summary of results 17 patients (15 male, 42 years), median CD4 456 ± 139/micro l were included so far. (uni-frankfurt.de)
  • All patients were followed every 3 months for 3 years to monitor efficacy (viral load [VL], CD4), tolerability, renal safety, regimen changes and resistance profile. (uni-frankfurt.de)
  • Over the median 2 years of follow-up, there were 20 ERC-adjudicated TB cases among 622 children in the co-trimoxazole analysis: 5 in the continue arm and 15 in the stop arm (hazard ratio (stop: continue) = 3.0 (95 % CI, 1.1-8.3), P = 0.028). (biomedcentral.com)
  • There were no significant differences between arms in median time to breastfeeding cessation (16 months) or incidence of severe, life-threatening, or fatal adverse events for mothers or infants (14 and 42 per 100 person-years, respectively). (medscape.com)
  • Nivolumab did not affect ART's ability to keep the viral load suppressed and the CD4 count stable. (eatg.org)
  • Most cases and controls had stable CD4 counts over recent months, men taking antiretrovirals had maintained undetectable loads, and viral loads in untreated men did not differ between cases and either group of controls. (natap.org)
  • Current guidelines also recommend stopping routine CD4 monitoring, provided patients are clinically stable and virologically suppressed. (prolekare.cz)
  • CD4 is a receptor for the human immunodeficiency virus (HIV). (thermofisher.com)
  • The CD4 antigen is involved in the recognition of MHC class II molecules and is a co-receptor for HIV. (thermofisher.com)
  • 4.12), sepsis (OR 6.98) and low total lymphocyte counts (OR 3.60) were associated with increased risk. (who.int)
  • Results: Total of 324 PLWH (63% females) who were on combination antiretroviral therapy for median of 144 months (IQR: 108-168) were investigated. (who.int)
  • A CD4 count within the preceding 3 months was available for 77% of LGV cases, 62% of symptomatic controls, and 71% of asymptomatic controls. (natap.org)
  • Median CD4 count reported within the past 3 months was statistically equivalent for cases (530), symptomatic controls (470), and asymptomatic controls (470). (natap.org)
  • Median time to death was 3.6 months (IQR= 1.4 to 10.7). (aidsmap.com)
  • The median follow-up time is 4 months. (uni-frankfurt.de)
  • Median ARI free duration (months) was shorter among those who developed PT compared to those developing non-PT category of ARI i.e. 30 (95% CI as 26,32) versus 67(95% CI as 60,71) in subgroup I and 47 (95% CI as 42,49) versus 80 (95% CI as 72,87) in subgroup II ( P (scirp.org)
  • All 14 patients with LR initially responded to dupilumab then developed worsening symptoms at a median of 4 months. (medscape.com)
  • This prospective study aimed to determine the safety of nivolumab in PLWH with a CD4 count less than 100/mL and an undetectable or very low viral load who have advanced cancers. (eatg.org)
  • The usual median time to achieve full viral suppression is about 100 days. (kit.nl)
  • Median travel time to the nearest surgical facility was 9 minutes, median travel time to the actual cancer surgery facilities was 22 minutes, and the median number of facilities bypassed was 3. (cdc.gov)
  • is markedly increased in patients infected with HIV with very low CD4 counts. (msdmanuals.com)
  • Most HIV patients, both in high-income and in resource-poor countries, also display an immunological response to treatment, measured as an increase in CD4 count. (kit.nl)
  • In modified vans (mobile units) parked at test locations, CommLink nurses provided physical and psychosocial assessment, clinical staging, CD4 count, syndromic treatment for sexually transmitted infections, and a 7-day course of cotrimoxazole ( Figure 2 ). (cdc.gov)
  • After statistical adjustment for age, sex, ethnicity, HIV risk group, CD4 count, certain comorbidities, and other potential confounders, incidence of any cancer (AIDS or non-AIDS) was similar in people who had taken an INSTI and in those who had not. (natap.org)
  • Eligibility criteria for ART included being under one year of age or having a CD4 percentage ≤ 20 or CDC clinical stage B or C. Follow-up data for patients were included through March 2007. (aidsmap.com)
  • 14 , 15 Furthermore, in two studies among adults with HIV not receiving ART, persons who developed TB disease had higher viral loads 16 and a greater risk of HIV disease progression 16 and death 17 than CD4-matched control patients without TB. (hiv.gov)
  • Immunohistochemically, both groups had a dysregulated (mostly increased) CD4:CD8 ratio. (medscape.com)
  • The first was to directly compare children randomised to monitoring with and without CD4 counts in terms of long-term VL suppression and resistance. (prolekare.cz)
  • In 14-25% of patients CD4 count does not rise substantially despite successful viral suppression. (kit.nl)
  • Several bNAbs have been tested to date in HIV-1-infected individuals, including the CD4-binding, site-specific antibodies VRC01, 3BNC117, VRC07-523LS and N6-LS, the V3-glycan-specific antibody 10-1074 and the V2-apex-specific antibodies PGDM1400 and CAP256-VRC26.25 (refs. (nature.com)
  • The presence of any cytopenia was associated with female sex, decreasing CD4 count and decreasing body mass index. (biomedcentral.com)